PN-235

Protagonist Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	PN-235
Also known as	Active Drug
Sponsor	Protagonist Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis (PHASE2)
A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants (PHASE1)
Pharmacokinetics of PN-235 in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PN-235 CI brief — competitive landscape report
PN-235 updates RSS · CI watch RSS
Protagonist Therapeutics, Inc. portfolio CI